Musk’s xAI, SpaceX combo is the biggest merger of all time, valued at $1.25 trillion
The record-setting deal will be the largest merger of all time and is valued at $1.25 trillion
Spain becomes first country in Europe to ban social media for under-16s
Spain’s Prime Minister Pedro Sanchez urges the protection of children from a “digital wild west.”
World’s largest jeweler under pressure as analysts warn it will be hit by volatile silver price
Jefferies analysts downgraded Pandora to Hold. Rising costs are squeezing its margins, as is a worsening macroeconomic backdrop.
PayPal shares plunge nearly 20% on CEO exit, disappointing 2026 profit forecast
PayPal logged revenue of $8.68 billion for the quarter, missing estimates of $8.80 billion. Adjusted profit was $1.23 a share, also below analysts’ forecasts.
Ray Dalio warns the world is ‘on the brink’ of a capital war
The billionaire Bridgewater founder also weighed in on investing in gold after the metal was gripped by a sharp sell-off.
Palantir soars after strong earnings. What analysts highlighted, including accelerating AI demand
Analysts remained overwhelmingly bullish on Palantir, although the company’s lofty valuation stood out as a sore spot for some.
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
The data on Pfizer’s GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
Disney shares are flat as CEO succession takes the spotlight. Here’s what’s happening
An analyst said the question of who will succeed Bob Iger as CEO has been an ‘overhang’ on Disney’s stock.
Nintendo Switch becomes the gaming giant’s best-selling console ever
The success of the Switch was down to the innovative nature of the hardware, combined with strong games based on Nintendo’s most popular characters.
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.
